Kinfo
Ionis Pharmaceuticals, Inc. logo

Ionis Pharmaceuticals, Inc.

IONSNASDAQHealthcare·US · USD
$43.50
-0.04 (-0.09%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap7.23B USD
Enterprise value7.32B USD
Trailing P/E-18.30
Forward P/E-39.14
PEG ratio0.10
Price / sales8.28
Price / book16.40
Profitability
Gross margin98.98%
Operating margin-38.18%
Profit margin-64.66%
Return on assets-12.43%
Return on equity-105.50%
Income (TTM)
Revenue874.09M USD
Gross profit-60.60M USD
EBITDA-579.48M USD
Net income-565.17M USD
Diluted EPS-$3.48
Rev. growth (YoY)-40.70%
Balance sheet
Total cash2.10B USD
Total debt2.19B USD
Debt / equity497.80
Current ratio7.89
Book value / share$2.66
Cash flow (TTM)
Operating cash flow-496.43M USD
Levered free cash flow-346.76M USD
Shares & price
Shares outstanding165.90M
Float164.82M
Held by institutions110.50%
Beta0.42
50-day MA$53.91
200-day MA$70.39
52-week high$86.74
52-week low$42.63
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-233.323.52+6.02%2026-04-29-0.77-0.30+61.04%2026-03-170.420.65+54.76%
About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Brett P. Monia Ph.D.
Employees
1,480
Headquarters
Carlsbad, CA, United States

Frequently asked questions about Ionis Pharmaceuticals, Inc.